Financial Performance - MRD revenue reached $49.9 million, a 42% year-over-year increase[6] - Excluding milestones, MRD revenue grew by 38% year-over-year[6] - Total revenue increased by 36% to $58.9 million[31] - Sequencing gross margin increased to 64%, up 14 percentage points year-over-year[6] - The company's cash position is strong at $222 million[6] - Q2 2025 cash burn was approximately $11 million, a 36% decrease compared to Q2 2024[6] MRD Business - Clinical testing revenue increased by 57% year-over-year in Q2 2025[9] - clonoSEQ US volume reached 24,624 tests in Q2 2025[10] - 44% of MRD tests were conducted in blood in Q2 2025[11] - MRD pharma backlog is approximately $218 million, a 21% year-over-year growth[19]